Without taking a firm position, the antitrust agency said Novo’s two-step deal structure may illegally sidestep requirements ...

The immune drugmaker is the second biotech, along with MapLight Therapeutics, to recently use a workaround in U.S. securities ...

The brain drug developer plans to slash R&D expenses by about 60% in the wake of the FDA surprisingly rejecting its rare disease drug Vyglxia.

Ahead of a reported White House deal meant to lower the cost of obesity drugs like Wegovy, Novo said “intensifying ...

Soleno shares fell double digits amid questions about the growth trajectory of its Prader-Willi drug. Elsewhere, a cancer ...

The startup is advancing a drug licensed from China’s Hengrui Pharma that it claims could be “best-in-class” among a group of ...

The deal hands Blackstone a piece of the potential future sales of an antibody-drug conjugate that could soon challenge marketed medicines from AstraZeneca and Gilead.

While the launches of Journavx and Casgevy have started to build steam, “investors may not be inclined to look past the clear ...

The obesity drug developer has declared a new proposal from Novo “superior” to Pfizer’s original bid as well as an updated ...

Still, CEO Doug Ingram claimed removing the two drugs, Vyondys 53 and Amondys 45, from market would make “little sense” and ...

The startup claims its medicines may be able to overcome the limitations of conventional antibody-drug conjugates by ...

Though many biotech investment firms have recently raised new funds to support young drugmakers, they’re cautious in deploying that cash in a turbulent economic climate. That hesitance has given ...